The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries

Table 2

Inhibition of U87MG, U87/EGFR, and U87/EGFRvIII cell growth by Iressa ± mechlorethamine (HN2), ZRBA4, and ZR2003, alone or in combination with 1 μM octreotide (OCT), as assessed by the alamar blue assay.

	U87	U87/EGFR	U87/EGFRvIII
	IC50 (μM)	IC50 (μM)	IC50 (μM)
OCT	n/a	n/a	n/a
Iressa	11.89±8.40	2.96±0.05	34.14±3.53
Iressa + OCT	13.01±9.70	3.27±0.28	32.23±3.80
HN2	9.58±1.20	1.52±0.59	19.74±2.85
HN2 + OCT	n/a	1.81±0.68	13.33±3.78
Iressa + HN2	14.51±0.20	0.77±0.27	15.82±1.97
Iressa + HN2 + OCT	12.24±1.53	0.66±0.13	n/a
ZRBA4	8.27±0.57	3.91±0.62	7.50±0.82
ZRBA4 + OCT	8.20±0.59	3.58±0.52	7.45±0.62
ZR2003	0.82±0.24	0.87±0.14	0.54±0.18
ZR2003 + OCT	0.77±0.19	0.73±0.08	0.43±0.14

Values are presented as mean ± SEM and are representative of 3 experiments run in triplicate.